ANRO on NYSE
Alto Neuroscience, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $45.6M | $47.0M |
| General and administrative | $20.7M | $21.6M |
| Total operating expenses | $66.4M | $68.6M |
| Loss from operations | -$66.4M | -$68.6M |
| Interest income | $6.6M | $8.9M |
| Interest expense | -$2.5M | -$1.4M |
| Loss on debt extinguishment | -$681.0K | $0 |
| Other, net | -$327.0K | -$297.0K |
| Total other income, net | $3.1M | $7.2M |
| Net loss | -$63.2M | -$61.4M |
| Change in fair value attributable to instrument specific credit risk | $153.0K | $0 |
| Foreign currency translation | -$30.0K | -$22.0K |
| Total other comprehensive income (loss) | $123.0K | -$22.0K |
| Comprehensive loss | -$63.1M | -$61.5M |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -$2.19 | -$2.50 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -$2.19 | -$2.50 |
| Weighted-average number of common shares outstanding, basic (in shares) | 28.9M shares | 24.6M shares |
| Weighted-average number of common shares outstanding, diluted (in shares) | 28.9M shares | 24.6M shares |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|
| Cash and cash equivalents | $176.5M | $168.2M | |
| Prepaid expenses and other current assets | $1.2M | $1.1M | |
| Total current assets | $177.7M | $169.3M | |
| Restricted cash | $500.0K | $500.0K | |
| Property and equipment, net | $1.9M | $2.7M | |
| Operating right-of-use asset | $4.3M | $5.0M | $5.2M |
| Other assets | $338.0K | $4.0K | |
| Total assets | $184.7M | $177.5M | |
| Accounts payable | $1.9M | $1.6M | |
| Accrued expenses and other current liabilities | $8.9M | $8.4M | |
| Term loan, current | $585.0K | $0 | |
| Total current liabilities | $11.3M | $10.0M | |
| Term loan, non-current | $16.2M | $10.3M | |
| Convertible Grant Agreement | $2.2M | $1.3M | |
| Lease liability, long-term | $3.8M | $4.5M | |
| Total liabilities | $33.5M | $26.1M | |
| Common stock (par value $0.0001), 500,000 shares authorized; 31,924 and 26,987 shares issued and outstanding as of December 31, 2025 and 2024 | $3.0K | $3.0K | |
| Additional paid-in capital | $352.8M | $290.0M | |
| Accumulated deficit | -$201.6M | -$138.4M | |
| Accumulated other comprehensive loss | $22.0K | -$101.0K | |
| Total stockholders equity | $151.1M | $151.5M | |
| Total liabilities and stockholders equity | $184.7M | $177.5M | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, authorized (in shares) | 500.0M shares | ||
| Common stock, outstanding (in shares) | 31.9M shares | 27.0M shares | |
| Common stock, issued (in shares) | 31.9M shares | 27.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$63.2M | -$61.4M |
| Stock-based compensation expense | $8.1M | $7.6M |
| Depreciation | $661.0K | $502.0K |
| Non-cash research and development license expense | $0 | $735.0K |
| Non-cash lease expense | $774.0K | $337.0K |
| Non-cash interest expense related to term loan | $729.0K | $393.0K |
| Loss on disposal of assets | $156.0K | $52.0K |
| Other | $327.0K | $297.0K |
| Loss on debt extinguishment | $681.0K | $0 |
| Prepaid expenses and other assets | $101.0K | -$463.0K |
| Accounts payable | $221.0K | $516.0K |
| Accrued liabilities and other liabilities | -$289.0K | $4.0M |
| Net cash used in operating activities | -$51.8M | -$47.4M |
| Capital expenditures | -$24.0K | -$2.1M |
| Net cash used in investing activities | -$24.0K | -$2.1M |
| Proceeds from sale of common stock and pre-funded warrants in private placement | $50.0M | $0 |
| Payments from sale of common stock and pre-funded warrants in private placement | -$167.0K | $0 |
| Proceeds from issuance of common stock from initial public offering | $0 | $137.6M |
| Payments on issuance cost from registration statement | -$556.0K | $0 |
| Proceeds from issuance of term loan, net | $19.7M | $0 |
| Repayment of former term loan | -$10.2M | $0 |
| Payment of loan financing cost | -$127.0K | $0 |
| Proceeds from Convertible Grant Agreement | $750.0K | $1.2M |
| Proceeds from exercise of stock options | $703.0K | $187.0K |
| Net cash provided by financing activities | $60.1M | $135.7M |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -$30.0K | -$11.0K |
| Net increase in cash, cash equivalents and restricted cash | $8.3M | $86.2M |
| Conversion of K2 term loan into shares of common stock | $3.7M | $0 |
| Issuance of warrants in connection with term loan | $524.0K | $0 |
| Costs from sale of common stock and pre-funded warrants in private placement not yet paid | $107.0K | $0 |
| Conversion of preferred stock into common stock upon completion of initial public offering | $0 | $141.5M |
| Reclassification of preferred warrant liability to equity | $0 | $1.6M |
| Reclassification of deferred offering costs to equity | $0 | $1.4M |
| Operating right-of-use asset obtained in exchange for lease obligation | $0 | $5.2M |
| Deferred offering and share issue costs not yet paid | $0 | $8.0K |
| Cash paid for interest | $1.7M | $999.0K |
Recent filings
- Oct 5, 20264
- Oct 1, 20264
- Sep 29, 2026144
- Aug 27, 20268-K
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G/A
- Aug 12, 20268-K
- Aug 12, 202610-Q
- Jul 27, 2026SCHEDULE 13G
- Jul 20, 2026SCHEDULE 13G
- Jul 14, 2026424B5
- Jul 14, 20268-K
- Jul 13, 20268-K
- May 29, 20263
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6